Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|March 24, 2020
Elligo Joins Efforts To Expand COVID-19 Risk Screening, Testing
Advertisement
Elligo Health Research, a healthcare-enabling research organization, is working with Verily to support the Project Baseline COVID-19 Program. The program is a collaboration with the California Governor’s office, federal, state and local public health authorities, to expand COVID-19 risk screening and testing. Three initial sample-collection sites were launched Monday, March 16 in San Mateo County and Santa Clara County. Additional locations are expected in the coming weeks.
“COVID-19 is presenting unprecedented challenges for our customers, partners and communities. In this extraordinary situation it is imperative that those of us in healthcare and clinical research work together to advance new and innovative ways to mitigate the risks of COVID-19,” said Chad Moore, Elligo President. “Whatever we can do to serve communities in need, we will.”
Elligo’s mission has always been to bring clinical research directly to clinical healthcare, solving patient access challenges by enabling research as a care option. Their existing capabilities enabled Elligo to immediately contribute to these important efforts. As the response to the COVID-19 pandemic evolves, Elligo remains committed to expanding access to healthcare to those in need and helping to better understand the epidemiology of the virus.
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
3
Where AI Governance in Clinical Development Falls Short
4
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
5